QIAseq SARS-CoV-2 Primer Panel
For targeted whole genome library preparation of SARS-CoV-2, the virus that causes COVID-19 disease
The QIAseq SARS-CoV-2 Primer Panel is specially designed to advance research into SARS-CoV-2, which is the causative agent of COVID-19 disease. This kit, when paired with a QIAseq FX DNA Library UDI Kit, is a solution for enriching and sequencing the entire viral genome. SARS-CoV-2 is encoded by a positive-sense, single-stranded RNA molecule that can be mixed with host RNA during isolation from a sample. The kit includes reagents to reverse transcribe the RNA into cDNA and primers to specifically enrich for its genome. The panel consists of over 200 primer pairs, covering the full 29.9 kb viral genome.
Want to try the QIAseq SARS-CoV-2 Primer Panel for the first time? Request a quote for a trial kit.
Want to try the QIAseq FX DNA Library UDI Kit for the first time? Request a quote for a trial kit.
The QIAseq SARS-CoV-2 Primer Panel is intended for molecular biology applications. This product is not intended for the diagnosis, prevention, or treatment of a disease.
High-quality, single-box solution
Targeting SARS-CoV-2 requires both reverse transcription and whole genome enrichment of the viral RNA. The QIAseq SARS-CoV-2 Primer Panel combines both of these steps to generate amplicons for downstream library creation. When paired with a QIAseq FX DNA Library UDI Kit, you can construct sequencing-ready libraries compatible with Illumina platforms.
Community primer design
QIAseq SARS-CoV-2 primer pools utilize designs from the ARTIC V3 primers. The primers have also gone through an in silico check to reduce chances for dimerization during sample enrichment.
Combine with a QIAseq FX DNA Library UDI Kit to enable multiplexing on high-throughput Illumina instruments, such as the NovaSeq (up to 384 samples per flow cell).
When paired with QIAGEN CLC Genomics Workbench, the panel can deliver data that can be quickly analyzed. Sequence data can be used to identify variants across different samples, as well as compare it to multiple genomes – from consensus reference genomes to one of many genomes that have been uploaded from around the world.
Viruses consist of nucleic acid (viral genome) and a limited number of proteins that facilitate entry into the host cell, replication of the genome and production of virions. While viral genomes can be comprised of RNA or DNA, SARS-CoV-2 is encoded by an RNA molecule. The size of the entire SARS-CoV-2 genome is under 30 kb and can be mixed with host RNA when isolating from a human sample, making it challenging to reconstruct the whole genome of the virus.
While next-generation sequencing (NGS) has become a vital tool, library preparation remains a key bottleneck in the NGS workflow. The QIAseq SARS-CoV-2 Primer Panel is a multiplex PCR primer set for whole genome amplification of SARS-CoV-2. Using primer pools that utilize designs from ARTIC V3 primers, the QIAseq SARS-CoV-2 Primer Panel generates amplicons that cover the entire SARS-CoV-2 genome. Combine with a QIAseq FX DNA Library UDI Kit to convert the amplicons into NGS-ready fragments compatible with lllumina sequencers.
From cDNA synthesis to enrichment
The QIAseq SARS-CoV-2 Primer Panel workflow begins with converting total viral RNA into cDNA using random priming (no rRNA depletion or poly-A selection is required). This reaction is flexible with regards to input RNA used for the reverse transcription reaction. To elaborate, 5 µl viral RNA input is required as a starting point. When the viral RNA has been previously assessed using a qPCR assay, the CT value should be between 18–35. If the CT is between 12–15, then dilute the sample 100-fold in water; if it's between 15–18 then dilute 10-fold in water. This will reduce the likelihood of PCR-inhibition.